Key Takeaways Labcorp acquired BioReference Health assets to strengthen its oncology diagnostics portfolio. The $225M deal includes $192.5M upfront and up to $32.5M in performance-based earnout. The acquisition expands patient and physician access to Labcorp's oncology testing services. Labcorp (LH) recently completed the acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health, Inc. (OPK) , a multinational biopharmaceutical and diagnostics company. This acquisition stre ...

FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics. “This recognition from ...

Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck CancersMISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Labquality Oy (Labquality), announce a novel external quality assessment (“EQA”) program to help ensure clinical laboratories accurately identify head and neck cancers associated with cancer-causing strains of Human Papilloma Virus (“ ...

PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are building out their best-in-class product portfolios and respective infrastructures to meet growing clinical demand fo ...

MISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Labquality Oy (Labquality), announce a novel external quality assessment (“EQA”) program to help ensure clinical laboratories accurately identify head and neck cancers associated with cancer-causing strains of Human Papilloma Virus (“HPV”). Labquality is introducing this novel EQA scheme at the 2025 meeting of the Europ ...

Co-Diagnostics Inc. CODX shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data.Check out the current price of CODX stock here.Strategic Partnership Fails to Sustain MomentumThe molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ PCR platform technolog ...

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comPHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced that Wendy Blosser, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. ...

Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne IRVINE, CA, and HERSTAL, BELGIUM – September 15, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the closing of the ExoDx business acquisition from Bio-Techne Corporation, which includes the ExoDx Prostate test. Acquisition of ExoDx Business On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnostics, Inc. fr ...

公司财务表现 - 公司上市10周年 股价从18美元IPO价格升至约170美元 实现近10倍回报 [3] - 公司收入从1.9亿美元增长至20亿美元 扩张约10倍 [3] - 过去十二个月收入增长44% 保持强劲增长势头 [3] - 最新季度处理超过85万次检测 产生5.466亿美元收入 [9] - 肿瘤检测业务占比22% 同比增长50% 成为关键增长引擎 [9] - 净亏损率从2021年的-75%改善至目前的-13% [14] 核心技术优势 - Signatera旗舰产品通过简单抽血实现个性化肿瘤知情检测 监测循环肿瘤DNA和分子残留病灶 [5] - 技术平台可检测血液中微小肿瘤DNA片段 为医生提供癌症进展和复发风险的前所未有洞察 [6] - 检测覆盖多种癌症类型包括乳腺、肺、卵巢、结直肠和膀胱癌 [5] - 提供Altera基因组分析和Empower遗传性癌症筛查 形成完整癌症护理解决方案组合 [6] 市场机遇规模 - 无细胞DNA检测市场预计五年内从110亿美元翻倍至200亿美元 [12] - 美国现有1900万癌症幸存者需要持续监测 代表巨大潜在市场 [10] - 公司预计未来几年可维持25%年收入增长 从去年17亿美元增至2030年70亿美元 [11] - 国际扩张机会巨大 目前98%收入来自北美 欧洲、亚太和拉丁美洲市场潜力达10-20亿美元 [17] 增长驱动因素 - 肿瘤学市场扩张机会达20-30亿美元 可超越现有癌症类型范围 [17] - 保险报销范围扩大将提升市场规模和定价能力 [18] - 医生采用度加深、保险覆盖扩大和标准护理整合带来增长空间 [17] - 可拓展至早期癌症检测、药物基因组学测试、遗传疾病筛查和器官移植监测等相邻市场 [17] 行业竞争格局 - 罗氏以160亿美元诊断收入领先市场 丹纳赫100亿美元 雅培90亿美元 [12] - 公司目前20亿美元收入规模表明仍处于增长早期阶段 [12] - 需要持续技术创新以维持无细胞DNA分析领域领导地位 [18] 估值前景分析 - 若达成70亿美元收入并维持13倍市销率 股价可能达到700美元 [13] - 即使市销率压缩至10倍 股价仍将超过500美元 [13] - 公司现金生成潜力可支持最小化股权稀释 [14] - 诊断市场渗透需要时间 长期估值可能达到500亿至2000亿美元 [15]

公司诉讼事件 - 罗森律师事务所宣布代表在2024年3月29日至2025年6月27日期间购买Unicycive Therapeutics公司(NASDAQ: UNCY)证券的股东提起集体诉讼 [1] - 诉讼指控公司存在虚假和/或误导性陈述 未能披露其过度夸大满足FDA生产合规要求的能力以及过度夸大氧化镧碳酸盐新药申请的监管前景 [2][3] - 诉讼声称当真相公开后 投资者遭受了损失 [3] 公司背景 - Unicycive Therapeutics是一家处于临床阶段的生物技术公司 [1] - 公司主要业务涉及氧化镧碳酸盐新药申请 [3] 法律程序 - 股东需在2025年10月14日前向法院申请担任首席原告 [4] - 律师事务所采用风险代理收费模式 股东无需支付任何费用或开支 [5] - 罗森律师事务所自成立以来已为股东追回超过10亿美元损失 [6] 行业动态 - 生物技术行业面临监管合规风险 [3] - 律师事务所专门处理投资者权利诉讼案件 [6]